Moreover, we propose that therapeutics that reactivate MHC-I expression and enhance anti-tumor immune cell infiltration in MYC-high tumors may improve the efficacy of immune checkpoint inhibitor therapies like anti-PD-1 and anti-PD-L1. Here, MYC is linked to neoplasm.